^
    ALK R1209Q
    Colon Cancer
    crizotinib + pazopanib
    Sensitive
    :
    C3
    Onco Targets Ther - 6d
    HER-2 positive
    CRC
    fam-trastuzumab deruxtecan-nxki
    Sensitive
    :
    C1
    Lancet Oncol - 1wk
    No biomarker
    CRC
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 2wk
    dMMR/MSI-H + TMB-L
    CRC
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 2wk
    PTEN mutation + MSI-H/dMMR
    CRC
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 2wk
    MSI-H/dMMR
    CRC
    pembrolizumab
    Sensitive
    :
    A1
    MSI-H/dMMR
    CRC
    nivolumab + ipilimumab
    Sensitive
    :
    A1
    BRAF V600E
    CRC
    cetuximab + binimetinib + encorafenib
    Sensitive
    :
    A1
    BRAF V600E
    CRC
    cetuximab + encorafenib
    Sensitive
    :
    A1
    No biomarker
    Colon Cancer
    capecitabine
    Sensitive
    :
    A1
    No biomarker
    Rectal Cancer
    FOLFIRI
    Sensitive
    :
    A1
    No biomarker
    Colon Cancer
    5-fluorouracil + irinotecan
    Sensitive
    :
    A1
    No biomarker
    CRC
    bevacizumab
    Sensitive
    :
    A1
    No biomarker
    Rectal Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Colon Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Colon Cancer
    Zirabev (bevacizumab biosimilar)
    Resistant
    :
    A1
    No biomarker
    CRC
    trifluridine/tipiracil
    Sensitive
    :
    A1
    No biomarker
    CRC
    ziv-aflibercept IV
    Sensitive
    :
    A1
    No biomarker
    CRC
    capecitabine
    Sensitive
    :
    A1
    EGFR expression
    CRC
    cetuximab
    Sensitive
    :
    A1
    KRAS Q61
    CRC
    cetuximab
    Resistant
    :
    A1
    No biomarker
    CRC
    ramucirumab
    Sensitive
    :
    A1
    No biomarker
    CRC
    panitumumab
    Sensitive
    :
    A1
    KRAS A146
    CRC
    cetuximab
    Resistant
    :
    A1
    No biomarker
    Rectal Cancer
    irinotecan
    Sensitive
    :
    A1
    No biomarker
    Colon Cancer
    irinotecan
    Sensitive
    :
    A1
    KRAS G13
    CRC
    cetuximab
    Resistant
    :
    A1
    KRAS G12
    CRC
    cetuximab
    Resistant
    :
    A1
    No biomarker
    CRC
    Aybintio (bevacizumab biosimilar)
    Sensitive
    :
    A1
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES